Rogier Rooswinkel

Invests in

Biotech

Investments

Per the firm's website.

Colleagues at Forbion

AH

Alexander Hoffmann

General Partner at Forbion

AV

Alice Vickers

Advisor at Forbion

AB

Antoine Boulanger Piette

Principal at Forbion

AC

Audrey Cacaly

Principal at Forbion

CI

Carlo Incerti

Operating Partner at Forbion

DK

Dirk Kersten

Managing Partner at Forbion

DH

Dmitrij Hristodorov

General Partner at Forbion

GM

Geert-Jan Mulder

Managing Partner at Forbion

Frequently asked questions

Who is Rogier Rooswinkel?

Rogier Rooswinkel is a General Partner at Forbion's Naarden office, which he joined in 2013, where he evaluates and structures new investment opportunities across disease areas with a focus on oncology. Before Forbion, he was a post-doctoral researcher at the Netherlands Cancer Institute (NKI) in the division of immunology, and during his studies he worked as an independent website designer and founded an IT company. He earned a PhD Cum Laude from the University of Amsterdam in 2013 for work at the NKI, and holds a Master's degree in Oncology from VU University Amsterdam.

Where does Rogier Rooswinkel work?

Rogier Rooswinkel is General Partner at Forbion.

What does Rogier Rooswinkel invest in?

Rogier Rooswinkel invests in Biotech.

What boards does Rogier Rooswinkel sit on?

Rogier Rooswinkel holds tracked board seats at Achilles, Amphista, Catalym, Granite, Loqus23, Pheon, Tessellate.

What companies has Rogier Rooswinkel invested in?

Investments tracked here include Enterprise, KaNDy, Replimune, Rigontec.

Where did Rogier Rooswinkel go to school?

Rogier Rooswinkel studied at Netherlands Cancer Institute (PhD (cum laude)); Vrije Universiteit Amsterdam (VU Amsterdam) (MSc, Oncology); Vrije Universiteit Amsterdam (VU Amsterdam) (BSc, Medical Natural Sciences).